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Remote or in-person breathing retraining for uncontrolled 
asthma symptoms
Asthma is a broad clinical syndrome and, in most 
settings, diagnosis is based on a compatible history of 
paroxysmal dyspnoea. The management of asthma is 
also predominantly influenced by reported episodes 
of breathlessness rather than specific objective 
measurements. Given this lack of precision, it is 
unsurprising that many people treated for asthma have 
persisting symptoms. To begin to address this issue, there 
has been welcome progress toward more personalised 
and targeted treatment for asthma subtypes.1,2 However, 
in the rush toward the use of biomarkers and precision 
medicines we should take care not to neglect the 
fundamentals of care, such as ensuring good inhaler 
technique and the provision of asthma action plans. 
Health-care professionals should also keep in mind 
their patients’ initial primary reason for seeking medical 
attention: to address their sensation of breathlessness.
It is well recognised that individuals treated for 
asthma often have breathlessness that exceeds what 
would be expected from their degree of lung disease. 
Approximately a third of people with asthma have 
features of hyperventilation syndrome as assessed 
though clinical history such as use of Nijmegen 
questionnaire.3 We also have an increasing understanding 
of the importance of other types of dysfunctional 
breathing,4 such as periodic deep sighing, thoracic 
dominant (apical) breathing, forced abdominal 
expiration, and thoraco-abdominal asynchrony. All of 
these dysfunctional breathing patterns appear to be more 
common in asthma than in the general population, and 
the degree of abnormality seems to be correlated with 
symptom scores when data are available.
With the development of specialist severe asthma 
multi-disciplinary teams,5 it is likely that there will be 
greater recognition of dysfunctional breathing in patients 
who are referred with difficult-to-treat symptoms. 
However, assessment and effective intervention6 from 
specialist physiotherapists is not available to most 
people with asthma. This situation of insufficient 
access to specialist health-care professionals risks costly 
progress up the therapeutic ladder driven by persistent 
symptoms and additional distress for patients. The study 
presented by Anne Bruton and colleagues7 in The Lancet 
Respiratory Medicine is therefore a welcome addition to 
the literature. This pragmatic randomised controlled 
trial evaluated whether breathing retraining improves 
asthma control in a broad population of patients 
with uncontrolled disease, and was not restricted to 
individuals suspected of having dysfunctional breathing. 
Crucially, the researchers also assessed whether the 
breathing retraining intervention could be acceptably and 
successfully delivered using a self-administered DVD with 
a supporting booklet. The scale and design of the study 
are laudable and attempt to provide a definitive answer 
to these questions.
The study found that both breathing retraining 
interventions—delivered either in face-to-face sessions or 
via the DVD and booklet—were associated with a better 
Asthma Quality of Life Questionnaire (AQLQ) score after 
12 months than usual care (adjusted mean difference 
in AQLQ between DVD intervention and  usual care was 
0·28, 95% CI 0·11–0·44). The DVD-based intervention 
was not inferior to face-to-face delivery of instructions 
in terms of total AQLQ score, and was experienced 
favourably by patients, despite greater user doubts as to 
its effectiveness. The number-needed-to-treat to see one 
individual achieving the minimum clinically important 
difference for AQLQ over usual care was eight, which 
was superior to that seen with medications commonly 
added to inhaled corticosteroids  (eg, an NNT of nine 
for formoterol).8 Unlike add-on therapies, however, 
breathing retraining was not associated with any change 
in other symptom measures, such as airflow obstruction 
or inflammation. As the authors point out, breathing 
retraining is an adjunct to appropriate pharmacotherapy 
and not a replacement.
The study by Bruton and colleagues7 provides strong 
evidence that breathing retraining delivered remotely 
via a DVD and booklet can be an effective intervention, 
but further work will be required to fully explore the 
generalisability of the findings. In common with 
similar recruitment approaches, the authors had a low 
response rate (10%) to the initial mailshot; those that 
did respond might not be representative of the wider 
asthma population. Indeed, the study population had a 
median age of 57 years and a mean Nijmegen score over 
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the threshold for hyperventilation.9 It therefore seems 
possible that this study population would be unusually 
likely to initiate and remain concordant with the 
intervention, which is consistent with the low drop-out 
rate observed. Older people with asthma also have higher 
anxiety scores than those aged under 40 years,10 and 
are more likely to be high consumers of short-acting β 
agonists,11 suggesting a greater scope for the intervention 
to be effective.
Further interesting research questions surround the 
future implementation of similar breathing retraining 
programmes. A move to online resources avoids the 
prohibitive costs associated with producing booklets 
and DVDs for the millions of people with asthma. The 
proposed delivery of an instructional video via the 
Asthma UK website is welcome and increases overall 
access to content. However, it is unclear whether 
engagement with web-based video is equivalent to that 
with a physical DVD and booklet, and how factors such 
as age and economic status might influence this. It could 
also be the case that individuals are more likely to access 
content if it is delivered by other routes, such as their 
usual streaming service.
Asthma outcomes have remained poor over recent 
years, with low expectations around control from patients 
and health-care providers. Remotely delivered breathing 
retraining is a key component toward incremental 
improvement, and a necessary adjunct to improved use of 
more tailored medical treatments.
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FENO and suspected asthma: better to identify 
responsiveness to treatment than to label with a diagnosis
In patients with non-specific respiratory symptoms, 
treatment with inhaled corticosteroids is often 
started on vague grounds. This situation is especially 
unfortunate because treatment tends to be continued 
for years. In The Lancet Respiratory Medicine, an 
important study by David Price and colleagues1 explores 
the use of the fraction of exhaled nitric oxide (FENO) as a 
predictor of a clinical response to inhaled corticosteroids 
in adult patients with respiratory symptoms, but 
no asthma diagnosis as yet, and with insignificant 
bronchodilator reversibility. In this randomised trial, 
4 weeks’ treatment with inhaled corticosteroids 
(QVAR Inhalation Aerosol 80 μg [Teva Respiratory, 
Amsterdam, Netherlands] two puffs twice per day, 
equivalent to 800 µg beclomethasone diproprionate 
per day) was compared with placebo, with patients 
stratified according to baseline FENO, defined as normal 
(≤25 parts per billion [ppb]), intermediate (>25 to 
<40 ppb), and high (≥40 ppb). A significant treatment 
effect on asthma control, as measured by change from 
baseline in the Asthma Control Questionnaire mean 
score, was seen only in patients with high FENO (mean 
score change 0·49, 95% CI 0·14–0·84). Furthermore, 
logistic regression revealed that FENO greater than 
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